Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Covid 19 Delta Variant
View:
Post by Duster340 on Jul 08, 2021 1:23pm

Covid 19 Delta Variant

on the rise, will ATE ever get P3 underway?)

(CNN)Twenty-four states have seen an uptick of at least 10% in Covid-19 cases over the past week, Johns Hopkins University data shows, as health experts and the federal government keep pressing for more people to get vaccinated.

The rapid spread of the Delta variant of the coronavirus has only ratcheted up the pressure.
That variant, first identified in India, accounted for 51.7% of all new Covid-19 infections in the country over the two weeks that ended Saturday, the US Centers for Disease Control and Prevention has estimated.
"We should think about the Delta variant as the 2020 version of Covid-19 on steroids," Andy Slavitt, a former senior adviser to Joe Biden's Covid Response Team, told CNN on Wednesday. "It's twice as infectious. Fortunately, unlike 2020, we actually have a tool that stops the Delta variant in its tracks: It's called vaccine."
 
 
For fully vaccinated people, the variant "presents very little threat to you, very unlikely that you're gonna get sick," he explained.
Full approval for vaccines from the US Food and Drug Administration could encourage more people to get vaccinated, Slavitt and other experts have said. The current vaccines distributed in the US are authorized for emergency use only. Full approval for the Pfizer vaccine could come as early as this month, Slavitt said Tuesday.
As of Wednesday, less than half of the US population -- 47.6% -- was fully vaccinated. The percentage of eligible people who were fully vaccinated -- ages 12 and up -- was 55.6%.
The case rate has been rising for the US as a whole. The country has averaged more than 15,060 new cases a day over the last week -- 20.7% higher than the average from the week prior, according to Johns Hopkins data.
The average is still well below this spring's peak -- an average of 71,320 daily for a week ending April 14 -- and the pandemic peak average of more than 251,000 daily for a week ending January 8.
In a grim reminder of the scale of the pandemic, the global death toll from Covid-19 has reached more than 4 million, data from Johns Hopkins on Wednesday showed.
Three countries account for more than a third of all global deaths. The US, which has the highest number of fatalities at 606,000, accounts for 15% of the global total, followed by Brazil and India.
Underscoring vaccines' effectiveness, researchers say the American toll would have been a lot worse without inoculations.
The US would have seen about 279,000 more Covid-19 deaths by June 28 had vaccinations -- which first became available in December -- not have taken place, according to researchers at Yale University and the Commonwealth Fund. The country also would have seen as many as 1.25 million additional hospitalizations, the researchers said.
Wearing face masks, people walk last month through Union Station in Los Angeles. California is one of the 24 states seeing an uptick in Covid-19 cases.
 
 

Fears about more variants if people don't get vaccinated

But the Delta variant is not the only one worrying health experts.
"Right now, you want to look at who's getting sick, whether from the Delta variant or any other variant: It's people who haven't been vaccinated," Dr. Megan Ranney told CNN on Wednesday.
"I don't want it to come to this, but I am hopeful that these surges will drive more people in those states with low vaccination rates to finally go out and get their shot."
Vaccinated people don't have much to worry about, said Ranney, an emergency physician at Rhode Island Hospital and an associate professor at Brown University.
But she offered an unsettling insight on the current surge of cases.
"What worries me more are the variants yet to come. And every time this virus is passed from one person to another, it has a chance to mutate. And it's only a matter of time until we have a variant against which the vaccines no longer protect us," she explained.
Some experts have begun asking whether it may be time to start testing vaccinated people to ensure the Delta variant does not evade the effects of vaccines.
Current federal guidelines say fully vaccinated people can refrain from routine testing. Studies and experts have also said the vaccines are still highly protective.
"I think now we should revisit this policy with the Delta variant and determine if the current recommendations hold up," Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, wrote in an email to CNN on Wednesday.
The CDC is only reporting data on "breakthrough" infections that cause severe disease. That could mean scientists and health officials will not know how many vaccinated people have mild or asymptomatic infections -- and it will be very difficult to track whether a new variant such as Delta is causing more vaccine failure.
Comment by themagicbox on Jul 08, 2021 3:33pm
Delta varient is not a concern. Viruses lose potency/lethality over time and trade off with spreadibility.  All indicators point to delta varient not being a concern. America is open for business.
Comment by WalkOverTheStrt on Jul 08, 2021 6:29pm
What would stop Antibe from taking only patients for PH3 ie the criteria as those that have recieved the covid vaccine?
Comment by IrishCanuck on Jul 08, 2021 10:53pm
Pfizer is developing a booster shot specifically against Delta lol It's not like companies made these vaccines in record time with scientists on one-year contracts and now threw their hands in the air
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities